Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled CM313 (SC) in systemic lupus erythematosus
CTR20250107Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in systemic lupus erythematosus (SLE), sponsored by Keymed Biosciences. Started Jan 2025; status: active.
02
Drugs
cm313
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20250107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250107.